TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3530649

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg orally)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31545636

Group type: EXPERIMENTAL
Intervention: Psychopathic traits
Number of subjects: 661

Group type: COMPARATOR
Intervention: Nonviolent or violent psychopath descriptions
Number of subjects: 661

Group type: COMPARATOR
Intervention: Nonviolent or violent person with schizophrenia descriptions
Number of subjects: 661

Group type: COMPARATOR
Intervention: Nondangerous person with depression description
Number of subjects: 661
Study: 28792857

Group type: EXPERIMENTAL
Intervention: Wearable resistance (WR) equivalent to 12% body mass (BM)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Traditional (TR) power clean training
Number of subjects: 16
Study: 24919820

Group type: EXPERIMENTAL
Intervention: 50mg ipragliflozin
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: 50mg or 100mg ipragliflozin (during open-label extension)
Number of subjects: 168
Study: 23489438

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 2312
Study: 20922415

Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii (250 mg twice a day for 10 days)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Metronidazole (30 mg/kg twice daily for 10 days)
Number of subjects: 48

Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 48
Study: 19773535

Group type: EXPERIMENTAL
Intervention: Repaglinide administered 1 hour after last gemfibrozil dose
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Repaglinide administered 24 hours after last gemfibrozil dose
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Repaglinide administered 48 hours after last gemfibrozil dose
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Repaglinide administered 96 hours after last gemfibrozil dose
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control phase (repaglinide without prior gemfibrozil)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Repaglinide metabolism inhibition continued up to 48 hours after gemfibrozil administration
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: CYP2C8 half-life estimation
Number of subjects: 9
Study: 16411026

Group type: EXPERIMENTAL
Intervention: Feeling Thermometer with Clinical Marker State (FT+)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Feeling Thermometer without Clinical Marker State (FT-)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Standard Gamble with Clinical Marker State (SG+)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Standard Gamble without Clinical Marker State (SG-)
Number of subjects: 182
Study: 14659717

Group type: EXPERIMENTAL
Intervention: Er:YAG laser treatment on normal enamel powder
Number of subjects: 5

Group type: COMPARATOR
Intervention: Er:YAG laser treatment on NaClO-treated enamel powder
Number of subjects: 5
Study: 11471363

Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 9549661

Group type: EXPERIMENTAL
Intervention: Pyridostigmine bromide 30 mg every 8 hours
Number of subjects: 0
Study: 8050422

Group type: EXPERIMENTAL
Intervention: Fibreoptic nasotracheal intubation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Orthodox nasotracheal intubation
Number of subjects: 30
Study: 3184782

Group type: EXPERIMENTAL
Intervention: 4-mg nicotine chewing gum
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31764076

Group type: EXPERIMENTAL
Intervention: Differentiated service delivery (DSD) eligibility screening
Number of subjects: 3465

Group type: COMPARATOR
Intervention: Not applicable (ineligibility reasons)
Number of subjects: 3465
Study: 31242752

Group type: EXPERIMENTAL
Intervention: Evinacumab (75/150/250 mg subcutaneously or 5/10/20 mg/kg intravenously) in SAD
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Evinacumab (150/300/450 mg subcutaneously once weekly, 300/450 mg every 2 weeks, or 20 mg/kg intravenously once every 4 weeks) in MAD
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo in SAD
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo in MAD
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo in MAD (intravenous)
Number of subjects: 139
Study: 28032482

Group type: EXPERIMENTAL
Intervention: Edoxaban 15 mg, once daily
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (normal renal function or mild renal impairment)
Number of subjects: 90
Study: 24668304

Group type: EXPERIMENTAL
Intervention: Healthy Choices (4-session motivational interviewing intervention)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study: 23537419

Group type: EXPERIMENTAL
Intervention: Study Group (SG) - telemedicine interactions (2 office visits at months 6 and 12, 2 telemedicine interactions at months 3 and 9)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control Group (CG) - quarterly office visits
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Study Group (SG)
Number of subjects: 100
Study: 22047812

Group type: COMPARATOR
Intervention: Lobeglitazone 0.5 mg (1 subject placebo)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Lobeglitazone 1, 2, 4, and 8 mg (8 subjects in each group, including 2 receiving placebos)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Lobeglitazone 1, 2, and 4 mg (once daily for 7 days, 8 subjects in each group, including 2 receiving placebos)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Lobeglitazone (various doses)
Number of subjects: 61
Study: 19672809

Group type: EXPERIMENTAL
Intervention: Online optical coherence pachymetry (OCP)
Number of subjects: 513

Group type: COMPARATOR
Intervention: Ultrasound pachymetry (USP)
Number of subjects: 513

Group type: COMPARATOR
Intervention: Comparison of OCP and USP
Number of subjects: 513
Study: 16388508

Group type: EXPERIMENTAL
Intervention: First screening round with PSA>or=3.0 ng/ml
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeat screening round with PSA>or=3.0 ng/ml
Number of subjects: 0
Study: 15372387

Group type: EXPERIMENTAL
Intervention: 22-gauge Quincke needle
Number of subjects: 60

Group type: COMPARATOR
Intervention: 25-gauge Quincke needle
Number of subjects: 60
Study: 11737964

Group type: EXPERIMENTAL
Intervention: NIDDM subjects
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: NIDDM subjects with complications
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control subjects (nondiabetic elderly)
Number of subjects: 15
Study: 9312760

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 4000 U per week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (hemodialyzed patients without EPO)
Number of subjects: 0
Study: 8349825

Group type: EXPERIMENTAL
Intervention: lovastatin (40 mg b.i.d.) + low cholesterol diet (mean 246 mg/d)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: lovastatin (40 mg b.i.d.) + high cholesterol diet (mean 1,071 mg/d)
Number of subjects: 12

Group type: COMPARATOR
Intervention: low cholesterol diet alone
Number of subjects: 12

Group type: COMPARATOR
Intervention: high cholesterol diet alone
Number of subjects: 12
Study: 2872813

Group type: COMPARATOR
Intervention: Terazosin (5, 10, or 20 mg once daily for four weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Terazosin (dose titration until maximum 20 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prazosin (dose titration until maximum 20 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31145384

Group type: EXPERIMENTAL
Intervention: Plyometric Training (PT)
Number of subjects: 2
Study: 29565235

Group type: EXPERIMENTAL
Intervention: Imagery training group practicing four team-level tactics by imagining team actions in specific game situations, three times a week for 4 weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: No imagery training (control group).
Number of subjects: 0
Study: 28556481

Group type: EXPERIMENTAL
Intervention: Reciprocity prime
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 26231610

Group type: EXPERIMENTAL
Intervention: Oral sodium bicarbonate therapy for 24 months
Number of subjects: 380

Group type: COMPARATOR
Intervention: Placebo for 24 months
Number of subjects: 380
Study: 24245948

Group type: EXPERIMENTAL
Intervention: Intensive education based on the Explore Transplant series of educational materials
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard-of-care ('usual') transplant education
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Intensive education
Number of subjects: 500
Study: 21145041

Group type: EXPERIMENTAL
Intervention: MK-0777 3 mg b.i.d. (n = 18)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: MK-0777 8 mg b.i.d. (n = 21)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (n = 21)
Number of subjects: 60
Study: 18922091

Group type: EXPERIMENTAL
Intervention: LLLT + NMES (7 J for 10 min)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: LLLT + NMES (3 J for 5 min)
Number of subjects: 5

Group type: COMPARATOR
Intervention: NMES only (Control)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Comparison between LLLT trials and Control
Number of subjects: 5
Study: 16542187

Group type: EXPERIMENTAL
Intervention: Inositol
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 12951904

Group type: EXPERIMENTAL
Intervention: Vitamin A in a single megadose
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 11077134

Group type: EXPERIMENTAL
Intervention: Captopril (6.25-12.5 mg)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Losartan (12.5-25 mg)
Number of subjects: 320
Study: 9228488

Group type: EXPERIMENTAL
Intervention: Intensively-treated patients with gestational diabetes mellitus
Number of subjects: 550

Group type: COMPARATOR
Intervention: Gestational diabetes mellitus patients who delivered at term
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Gestational diabetes mellitus patients who delivered preterm
Number of subjects: 550
Study: 8394646

Group type: EXPERIMENTAL
Intervention: DTaP vaccine
Number of subjects: 97

Group type: COMPARATOR
Intervention: DTwP vaccine
Number of subjects: 97
Study: 2887553

Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Anticholinergics
Number of subjects: 90
Study: 29230548

Group type: EXPERIMENTAL
Intervention: cis100 + RT (conventional radiotherapy with cisplatin 100 mg/m2 on days 1, 22, and 43)
Number of subjects: 62

Group type: COMPARATOR
Intervention: cis40 + ART (accelerated radiotherapy with cisplatin weekly 40 mg/m2)
Number of subjects: 62
Study: 28454835

Group type: EXPERIMENTAL
Intervention: Nateglinide and Valsartan
Number of subjects: 9306
Study: 25460855

Group type: EXPERIMENTAL
Intervention: Amiodarone discontinuation (group 1)
Number of subjects: 112

Group type: COMPARATOR
Intervention: No amiodarone discontinuation (group 2)
Number of subjects: 112
Study: 24159603

Group type: EXPERIMENTAL
Intervention: ACTH gel (16 units)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: ACTH gel (32 units)
Number of subjects: 23
Study: 21390311

Group type: EXPERIMENTAL
Intervention: Favorable SNP variants (CC, AA, TT)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: IP-10 below 150 pg/mL among genotype 1 infected carriers of favorable alleles
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Baseline IP-10 and C genotype at rs12979860
Number of subjects: 253
Study: 18991255

Group type: EXPERIMENTAL
Intervention: Lightweight (poliglecaprone‐polypropylene composite)
Number of subjects: 392

Group type: COMPARATOR
Intervention: Heavyweight (polypropylene)
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 392
Study: 16447057

Group type: EXPERIMENTAL
Intervention: GLP-1 (1.2 pmol kg(‐1) min(‐1))
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 14530465

Group type: EXPERIMENTAL
Intervention: 99mTc-P829 scintigraphy (approximately equal to 740 MBq)
Number of subjects: 44
Study: 12578881

Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 641

Group type: COMPARATOR
Intervention: Nonuse of statins
Number of subjects: 641
Study: 10488976

Group type: EXPERIMENTAL
Intervention: Cricopharyngeal myotomy
Number of subjects: 125

Group type: COMPARATOR
Intervention: No myotomy (Control)
Number of subjects: 125
Study: 8760715

Group type: EXPERIMENTAL
Intervention: Bilateral wedge resection (performed 6 months to 1 year prior)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Oral glucose tolerance test (100 g)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (normally menstruating women of similar age and BMI, n = 15)
Number of subjects: 15
Study: 1887969

Group type: EXPERIMENTAL
Intervention: Local anaesthesia by retrobulbar block
Number of subjects: 20

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 20
Study: 6347995

Group type: EXPERIMENTAL
Intervention: Misonidazole 2.5 gm/m2 once a week for six weeks (total dose 15 gm/m2) plus radiotherapy (5100 cGy over 6 weeks)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Conventional radiation therapy (6000 cGy/6-7 weeks) plus BCNU (80 mg/m2 on days 3, 4, 5, repeated q 8 weeks for 2 years)
Number of subjects: 245
Study: 3469101

Group type: EXPERIMENTAL
Intervention: 100 mg slow-release formulation of diclofenac sodium
Number of subjects: 0
Study: 29618101

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 28895878

Group type: EXPERIMENTAL
Intervention: Oat betaglucans (1.53 g of β‐glucan) administered three times daily before meals for two weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (Plac) administered three times daily before meals for two weeks
Number of subjects: 14
Study: 26571899

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS) applied to bilateral Hegu (LI 4) and Neiguan (PC 6) for 30 min, with dense‐disperse wave, 2 Hz/100 Hz in frequency.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham-stimulation applied to the acupoints with the lamp on but without electric current output.
Number of subjects: 40
Study: 24175595

Group type: EXPERIMENTAL
Intervention: Whole-body vibration training
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Eccentric training
Number of subjects: 58

Group type: COMPARATOR
Intervention: Wait-and-see approach
Number of subjects: 58
Study: 21396122

Group type: EXPERIMENTAL
Intervention: Problem solving therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supportive counselling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioural exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Psychoeducation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of interventions
Number of subjects: 0
Study: 18478129

Group type: EXPERIMENTAL
Intervention: Intravenous moxifloxacin (400 mg daily) for 5 days starting within 36 hours after stroke onset
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo for 5 days starting within 36 hours after stroke onset
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intravenous moxifloxacin (400 mg daily) for 5 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo for 5 days
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intravenous moxifloxacin (400 mg daily)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 80
Study: 16509866

Group type: EXPERIMENTAL
Intervention: peginterferon alpha‐2a (40 kDa)/ribavirin for 24 weeks (group A)
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: peginterferon alpha‐2a (40 kDa)/ribavirin for 48 weeks (group B)
Number of subjects: 491

Group type: COMPARATOR
Intervention: no treatment for 72 weeks (group C)
Number of subjects: 491
Study: 12483413

Group type: EXPERIMENTAL
Intervention: FDG-PET positive patients
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: High standardized uptake value (SUV)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: FDG-PET imaging
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: FDG-PET imaging in untreated patients
Number of subjects: 46
Study: 10686040

Group type: EXPERIMENTAL
Intervention: Bambuterol (10 mg oral solution once daily)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Terbutaline (0.075 mg/kg oral solution three times daily)
Number of subjects: 155
Study: 8994466

Group type: EXPERIMENTAL
Intervention: PCA (patient-controlled intravenous opioid analgesic administration)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: naproxen
Number of subjects: 75

Group type: COMPARATOR
Intervention: codeine
Number of subjects: 75
Study: 8398438

Group type: EXPERIMENTAL
Intervention: Co-amoxiclav (250 mg amoxycillin plus 125 mg clavulanic acid, eight-hourly)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Penicillin V (250 mg phenoxymethylpenicillin, six-hourly)
Number of subjects: 79
Study: 3510944

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with chlorambucil and cisplatin
Number of subjects: 369

Group type: COMPARATOR
Intervention: Sequential therapy with chlorambucil and cisplatin
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Second-line treatment with cisplatin after initial chlorambucil failure
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Surgically documented complete response rate
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Survival rates
Number of subjects: 369
Study: 31518482

Group type: EXPERIMENTAL
Intervention: HBV immunization
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: HBV DNA testing
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Mean viral load for OBI-positive cases
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Testing of parents of OBI-positive children
Number of subjects: 1200
Study: 29984710

Group type: EXPERIMENTAL
Intervention: Endocrowns made of lithium disilicate ceramic (IPS e.max CAD)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Endocrowns made of Solidex microhybrid composite
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Endocrowns made of Grandia microhybrid composite
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (Group IN)
Number of subjects: 40
Study: 27052296

Group type: EXPERIMENTAL
Intervention: Whole-brain radiotherapy combined with sodium glycididazole at a dose of 700mg/m² intravenous infusion 30 minutes before radiotherapy, three times a week
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Whole-brain radiotherapy combined with sodium glycididazole
Number of subjects: 64

Group type: COMPARATOR
Intervention: Whole-brain radiotherapy
Number of subjects: 64
Study: 24813752

Group type: EXPERIMENTAL
Intervention: Combined CoQ10 and clomiphene citrate
Number of subjects: 101

Group type: COMPARATOR
Intervention: Clomiphene citrate alone
Number of subjects: 101
Study: 23044701

Group type: EXPERIMENTAL
Intervention: Alfacalcidol (active form of vitamin D3)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (no alfacalcidol)
Number of subjects: 107
Study: 21400753

Group type: EXPERIMENTAL
Intervention: Cycloferon combined with lamivudine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cycloferon combined with a-interferon
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cycloferon
Number of subjects: 0
Study: 18321512

Group type: EXPERIMENTAL
Intervention: Electromagnetic stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study: 16390366

Group type: EXPERIMENTAL
Intervention: 0.5 g/day omega-3 fatty acids
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 1.4 g/day omega-3 fatty acids
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 2.8 g/day omega-3 fatty acids
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combined groups of omega-3 fatty acids
Number of subjects: 16
Study: 12563203

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 447

Group type: COMPARATOR
Intervention: Carotid angioplasty and stenting (CAS)
Number of subjects: 447
Study: 10994618

Group type: EXPERIMENTAL
Intervention: H. pylori eradication treatment (n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 20
Study: 9093339

Group type: EXPERIMENTAL
Intervention: Terbutaline (500 micrograms)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Histamine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Adenosine monophosphate (AMP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Histamine and AMP
Number of subjects: 20
Study: 8237525

Group type: EXPERIMENTAL
Intervention: Pefloxacin
Number of subjects: 96

Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 96
Study: 4006647

Group type: EXPERIMENTAL
Intervention: ursodeoxycholic acid, 800 mg/day
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: ursodeoxycholic acid, 400 mg/day
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: chenodeoxycholic acid, 750 mg/day
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: chenodeoxycholic acid, 375 mg/day
Number of subjects: 39

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 39
Study: 30930022

Group type: EXPERIMENTAL
Intervention: GS-4774 (2, 10, or 40 yeast units) with Tenofovir Disoproxil Fumarate (TDF) 300 mg daily
Number of subjects: 195

Group type: COMPARATOR
Intervention: TDF 300 mg daily
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: GS-4774
Number of subjects: 195
Study: 28507171

Group type: EXPERIMENTAL
Intervention: big ET‐1 (≤300 pmol/min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: intravenous placebo
Number of subjects: 10
Study: 25252699

Group type: EXPERIMENTAL
Intervention: Ospemifene 60 mg/day
Number of subjects: 919

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 919
Study: 23897954

Group type: EXPERIMENTAL
Intervention: Luminal A-like (LA-like)
Number of subjects: 1951

Group type: EXPERIMENTAL
Intervention: Luminal B-like (LB-like)
Number of subjects: 1951

Group type: EXPERIMENTAL
Intervention: HER2 positive
Number of subjects: 1951

Group type: EXPERIMENTAL
Intervention: Triple negative (TN)
Number of subjects: 1951
Study: 21877761

Group type: EXPERIMENTAL
Intervention: Ipragliflozin (ASP1941), doses ranging from 5-600 mg, administered once daily for 10 days
Number of subjects: 0
Study: 19236490

Group type: EXPERIMENTAL
Intervention: Minimally invasive craniopuncture therapy
Number of subjects: 465

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 465